In some cases, minor changes were made to the wording to bring the language and style up to date, without changing the meaning. We also made some changes without an evidence review: The age range was removed from recommendation 1.1.1 for clarity. The threshold for treatment in recommendations 1.1.4, 1.1.17 and 1.1.19 has been changed because of new health economics results. Recommendation 1.1.15 was amended to include all cardiovascular diseases. In recommendation 1.1.16, the bullet point about type 2 diabetes was deleted because the committee made separate specific recommendations for this subgroup. The list of underlying medical conditions in recommendation 1.1.18 has been updated. In recommendation 1.1.21, the age value has been changed to 85, as this is the upper limit of the QRISK2 assessment tools. The part on treatment has been deleted, as recommendations on treatment are listed in section 1.4. In recommendation 1.1.27, the words 'long-term' have been added to emphasise the need to discuss people's views about taking medication long term. Recommendation 1.1.28 has been amended to highlight the importance of the person's involvement in decision making and that their choices are adequately recorded. Recommendations 1.3.7 and 1.3.9 were updated because the chief medical officer issued changes to recommendations on physical activity in 2011. In recommendation 1.4.22, the reference to fasting was deleted because the committee considered that a fasting sample is not necessary if non-high-density lipoprotein (HDL) cholesterol is measured (see recommendation 1.4.4). They also wished to highlight the importance of taking a lipid sample also on admission. These recommendations are marked [2008, amended 2014]. Minor changes since publication July 2022: Recommendations 1.4.48 to 1.4.50 have been updated in line with NICE's technical appraisal guidance on icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. 